-
Mashup Score: 6Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s - 11 hour(s) ago
Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes. “Anti-TNF treatment failure is common, with a quarter of patients having primary nonresponse and a third of initial responders losing
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 12
Maralixibat improved pruritus and predictors of native liver survival in PFIC (eg, serum bile acids). Maralixibat represents a non-surgical, pharmacological option to interrupt the enterohepatic circulation and improve the standard of care in patients with PFIC.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 45
A no-drain policy is safe in terms of major morbidity and reduced the detection of grade B or C POPF, and should be the new standard approach in eligible patients undergoing distal pancreatectomy.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 15
On April 17, 2024, Scotland’s Parliament approved a 30% increase to the price per unit of alcohol sold in the country. The ruling means the minimum unit price (MUP) will rise from £0·50 per unit to £0·65 from this September.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2U.S. Lags Behind Other Countries in Hepatitis-C Treatment - 10 day(s) ago
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
Source: www.nytimes.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 6Dietary Interventions Beat Medication in IBS Treatment - 13 day(s) ago
Both a low-FODMAPs and low-carb diet led to a larger decrease in symptom severity
Source: www.medpagetoday.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5Dietary interventions a promising first line treatment for IBS - 14 day(s) ago
Dietary interventions such as low FODMAP should be considered a potential first-line treatment for patients with IBS, outperforming symptom-targeted medication in reducing symptom severity, a study suggests. However, all interventions in the single centre study resulted in significant and clinically meaningful efficacy at improving gastrointestinal, psychological and non-gastrointestinal somatic symptoms, and quality of life, the […]
Source: thelimbic.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 3Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial - 14 day(s) ago
Odevixibat could be an efficacious non-surgical intervention to improve pruritus, reduce serum bile acids, and enhance the standard of care in patients with Alagille syndrome. Longer-term safety and efficacy data of odevixibat in this population are awaited from the ongoing, open-label ASSERT-EXT study.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 12
Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langas
Source: www.buzzsprout.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 45Urgent action needed to achieve viral hepatitis elimination - 15 day(s) ago
The headline figures from WHO’s 2024 Global Hepatitis Report, released at the World Hepatitis Summit in Lisbon, Portugal, on April 9, make for stark reading. 1·3 million people died from viral hepatitis in 2022: the same number as killed by tuberculosis, second only to COVID-19 as the leading communicable cause of death, and an increase on the 2019 estimate of 1·1 million. There were 1·2 million new hepatitis B infections and almost 1 million new hepatitis C infections in 2022—marginally lower than 2019 estimates, but not substantially so.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s https://t.co/3rK5IZDWT9 via @HealioGastro